Agile Therapeutics (AGRX) Receives Average Rating of “Hold” from Brokerages

Shares of Agile Therapeutics (NASDAQ:AGRX) have been assigned an average rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $7.67.

Several equities analysts have recently commented on AGRX shares. HC Wainwright set a $8.00 price objective on Agile Therapeutics and gave the company a “buy” rating in a research report on Friday, December 22nd. Janney Montgomery Scott downgraded Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $5.00 price objective on shares of Agile Therapeutics in a research report on Friday, December 22nd. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, December 22nd. Finally, William Blair downgraded Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th.

How to Become a New Pot Stock Millionaire

Several institutional investors have recently made changes to their positions in AGRX. Bank of New York Mellon Corp increased its holdings in shares of Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 20,654 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after purchasing an additional 27,907 shares during the last quarter. OxFORD Asset Management LLP bought a new stake in shares of Agile Therapeutics in the third quarter worth about $161,000. Dimensional Fund Advisors LP increased its holdings in shares of Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after purchasing an additional 82,213 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Agile Therapeutics by 3.4% in the fourth quarter. Franklin Resources Inc. now owns 2,867,800 shares of the specialty pharmaceutical company’s stock worth $7,714,000 after purchasing an additional 95,600 shares during the last quarter. Institutional investors and hedge funds own 71.03% of the company’s stock.

Agile Therapeutics stock opened at $2.87 on Friday. Agile Therapeutics has a 52-week low of $1.93 and a 52-week high of $5.60. The company has a market capitalization of $98.29, a PE ratio of -3.12 and a beta of 1.91.

ILLEGAL ACTIVITY WARNING: “Agile Therapeutics (AGRX) Receives Average Rating of “Hold” from Brokerages” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3298555/agile-therapeutics-agrx-receives-average-rating-of-hold-from-brokerages.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Expect Bank Of Princeton  to Post $0.51 EPS
Zacks: Analysts Expect Bank Of Princeton to Post $0.51 EPS
Energen  Earns Buy Rating from Stephens
Energen Earns Buy Rating from Stephens
Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.